This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
5/13/2026
Thank you very much for joining FY2025Q4 Learning School for Takeda Pharmaceutical Company. An O'Reilly IR head, I will serve as MC.
First, language setting.
For those of you who wish to listen to this call in English, please select English in the Zoom language select button. Before starting, I'd like to remind everyone that we will be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results made different materially from those discussed today. The factors that could cause actual results to differ materially are discussed in our most recent Form 20F and in our other SEC findings.
You're reading a preview of the 4502.T Q4 2025 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing